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Abstract
Purpose Only a minority of patients with oropharyngeal squamous cell carcinoma (OPSCC) are diagnosed without regional 
metastasis (cN0). Studies focusing on the management of cN0 neck in OPSCC are scarce.
Methods We reviewed all OPSCC patients treated at our institution with cN0 neck between 2000 and 2009. The treatment 
of neck and pattern of regional control was analyzed. Median follow-up was 5 years (range 3.5–9.0) or until death.
Results Of the total 313 OPSCC patients treated within the period, 56 (18%) presented with cN0 neck. Of them, 51 (91%) 
received completed treatment with curative intent: 46 (90%) underwent elective neck treatment with either neck dissection 
± (chemo)radiotherapy (C)RT (n = 23) or (C)RT (n = 23). A regional recurrence occurred in three patients (6%) and they all 
had a p16-negative soft palate midline primary tumor. Two of these patients had received RT on the neck.
Conclusions While the overall prognosis of OPSCC is generally favorable and regional recurrences are infrequent, soft pal-
ate tumors, that are usually p16 negative, may form an subgroup warranting more aggressive treatment despite the clinical 
appearance of early stage.
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Introduction
One of the most current issues in head and neck oncology 
is the treatment of oropharyngeal squamous cell carcinoma 
(OPSCC) [1, 2]. The incidence of the HPV-related OPSCC 
is increasing [3]. It has been shown to have remarkably bet-
ter prognosis compared with HPV non-related OPSCC, 
which is typically associated with long-term tobacco and 
alcohol consumption [4]. This has raised concern about pos-
sible overtreatment of HPV-related OPSCC and unneces-
sary treatment-related morbidity [5]. Ongoing studies are 
examining whether the treatment of patients diagnosed with 
HPV-related OPSCC could be de-escalated without compro-
mising survival [1, 2].
Traditionally, treatment options for OPSCC include either 
primary surgery with or without postoperative (chemo)
radiotherapy ([C]RT) or definitive (C)RT with surgery as 
a salvage option. These treatment options are considered to 
be equal in terms of survival outcome. However, the cur-
rent opinions are derived from retrospective evaluations [6]. 
Currently, many prospective randomized trials on OPSCC 
management are ongoing, but still unfinished [2]. In many 
centers, definitive (C)RT has been favored in the treatment 
of tongue base tumors because of the high morbidity related 
to open surgical treatment. Recently, transoral robotic sur-
gery has been developed to enable transoral removal of small 
(T1–T2) previously transorally inaccessible OPSCC tumors 
with low morbidity [7]. Further, the chosen treatment modal-
ity of the neck often corresponds to the treatment of the 
primary tumor.
Oropharyngeal cancer typically presents with a lump in 
the neck as the first symptom [8]. Especially, HPV-related 
OPSCC is often characterized by a small primary tumor with 
advanced neck disease. We have previously evaluated man-
agement of the neck with clinically detected regional lymph 
node metastasis (cN+) in OPSCC [9]. Only a minority of 
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OPSCC patients present without clinically detected regional 
lymph node metastasis at the time of diagnosis (cN0) [10]. 
According to a common principle, elective neck treatment 
is indicated if the risk of occult metastasis is considered to 
be at least 15–20% [11]. Studies focusing on this subgroup 
of patients are infrequent. In this study, we retrospectively 
evaluated treatment approaches and outcome of cN0 OPSCC 
patients in a 10-year series at our institution. Special empha-
sis was placed on the occurrence of regional recurrences and 
on the factors associated with regional failures.
Materials and methods
A total of 331 unselected consecutive patients were diag-
nosed with an oropharyngeal malignancy at the Helsinki 
University Hospital between 1st January 2000 and 31st 
December 2009 [9, 12]. From further analysis, we excluded 
those who had histology other than squamous cell carci-
noma (n = 18), or had concurrent or earlier treatment for 
a head and neck malignancy (n = 16), or had a cN+ dis-
ease (n = 241). A total of 56 patients with a cN0 neck were 
included. Treatment with curative intent was initiated for 
52 patients with a primary OPSCC and cN0 neck (Fig. 1). 
Clinicopathological data on patient and tumor characteris-
tics, treatment, and follow-up were manually recorded from 
hospital regiestries. Dates and causes of death were provided 
by the Statistics Finland, and this data include fatal events 
caused by various cancer-related factors. Of the 52 patients, 
imaging methods prior to TNM assessment included mag-
netic resonance imaging of the neck in 44 patients, computed 
tomography in 32 patients and ultrasound in 6 patients. One 
patient underwent a sentinel lymph node biopsy (SLNB). 
Baseline clinicopathological data of the 52 patients with 
curative treatment intent are presented in Table 1. Institu-
tional Research Ethics Committee of the Hospital District 
of Helsinki and Uusimaa approved the study design and a 
research permission was granted for the study. Tissue Micro-
array (TMA) method served in p16 expression evaluation 
from primary tumors as described elsewhere [13]. Median 
follow-up was 5 years (range 3.5–9.0) or until death.
SPSS Version 21.0 (SPSS, Inc., Chicago, IL, USA) 
served in statistical analysis of the data. Kaplan–Meier 
estimate with the log-rank test was used to study the 
survival of patients over the time. The follow-up time in 
recurrence-free survival (RFS) and regional recurrence-
free survival (RRFS) were defined as time between treat-
ment completion and detection of recurrence in RFS and 
regional recurrence in RRFS or end of follow-up. Only 
detection of recurrence was defined as an event. The fol-
low-up time in disease-specific survival (DSS) was defined 
as time between treatment completion and end of follow-
up or death with disease, and in overall survival (OS) as 
time between treatment completion and end of follow-up 
or death of any cause. A Chi-square test was used to cross-
tabulate categorical data. Asymptotic and exact p values 
were used when best suitable. A double-sided p value 
below 0.05 was considered statistically significant.
Results
Treatment of the primary tumors
Table 2 shows the treatment modalities for the primary 
tumors according to different T classes and p16 status. 
Altogether, single treatment modality was given to 10 
patients (surgery alone 7 and RT alone 3), definitive CRT 
was delivered to 15 patients, and 26 underwent surgery 
followed by (C)RT. Salvage surgery due to residual pri-
mary tumor after (C)RT was performed in one case. One 
patient died during postoperative RT.
Table 1  Baseline clinical characteristics of the 52 N0 OPSCC 
patients with curative treatment intent
a In eight patients, p16 status was not available
Lateral wall tonsils and tonsillar pillars, Anterior wall base of tongue 
and vallecula, Superior wall soft palate and uvula
p16 positive p16 negative p value
No of  patientsa 52 20 24
Sex
 Male 36 14 18 0.711
 Female 16 6 6
Smoking
 Never 4 3 0 0.003
 Earlier 11 6 3
 Currently 28 6 18
HPV
 Positive 15 14 1 < 0.001





 T1 8 2 5 1.000
 T2 30 13 13
 T3 3 2 0
 T4a 11 3 6
Site
 Lateral wall 23 14 5 0.001
 Anterior wall 11 3 7
 Superior wall 16 2 12
 Posterior wall 2 1 0
1207European Archives of Oto-Rhino-Laryngology (2019) 276:1205–1210 
1 3
Treatment of the neck
Table 3 shows the given neck treatment according to T 
class. Five patients were followed up only. An elective neck 
dissection was carried out in 23 patients (20 ipsilateral and 
3 bilateral) including levels I–V in 12 patients, levels I–IV 
in 7 patients, and levels I–III in 3 patients. Contralateral ND 
included levels I–III in two patients. The information on the 
extent of one bilateral ND was not available. One patient 
underwent a bilateral salvage ND (ipsilateral and contralat-
eral levels I–V) after definitive CRT. Elective RT was given 
to 22 patients (15 of them had also concomitant chemother-
apy due to a large primary tumor). One patient underwent 
SLNB, which revealed a metastasis and thus therapeutic RT 
was delivered. Of the 33 surgically treated patients, 26 (79%) 
received postoperative (C)RT, and they all had RT both to 
the primary tumor site and to the neck.
Occult neck disease
An occult regional metastasis was observed in altogether 
7 (22.6%) out of the 31 patients who either underwent ND 
(in 5 out of 25 cases), or SLNB (in 1 case), or watchful 
observation without elective neck RT (in 1 out of the 5 cases 
4 months after diagnosis). Of these 7 occult metastases, 2 
developed in the 21 patients (2/21, 9.5%) with early local 
OPSCC (T1–T2) and 5 developed in the 10 patients (5/10, 
50%) with advanced local OPSCC (T3–T4).
Recurrences
Of the 51 patients with completed treatment, an isolated 
regional recurrence (no recurrence at the primary site) devel-
oped in three (5.9%) patients (Table 4). They all had had a 
T2N0 p16-negative midline soft palate primary tumor, that 
had been treated with surgery. None of them had had elec-
tive ND, but two had received RT to the neck. Three patients 
Fig. 1  Flowchart of the patients 
with cN0 OPSCC
Table 2  Treatment modality of the 51 patients with a completed 
treatment for N0 oropharyngeal squamous cell carcinoma according 
to T class and p16 status
Sx surgery, RT radiotherapy, CRT chemoradiotherapy
a One patient underwent salvage surgery after CRT 





T1 5 1 0 0 2
T2 2 16 1 3 8
T3 0 2 0 0 1
T4 0 3 3 0 4a
Total 7 22 4 3 15
p16+ (20) 1 9 3 1 6
p16− (23) 5 12 0 1 5
Table 3  Treatment to the neck of the 51 patients with completed 
treatment for cN0 disease according to T class
ND neck dissection, RT radiotherapy
Follow-up ND RT ND + RT RT + ND
T1 4 1 3 0 0
T2 1 1 15 13 0
T3 0 0 1 2 0
T4 0 0 3 6 1
Total 5 2 22 21 1
1208 European Archives of Oto-Rhino-Laryngology (2019) 276:1205–1210
1 3
developed a local recurrence without regional involvement, 
and one patient experienced a distant recurrence without 
locoregional recurrence.
Survival
The 5-year RRFS for the whole population was 93.8%. The 
5-year RRFS for the patients with elective neck treatment 
was 95.2%, and for the patients with neck follow-up only 
was 80.0% (p = 0.153). The 5-year DSS for patients with 
either elective neck treatment or neck follow-up only were 
81.5% and 75.0% (p = 0.815) and the corresponding figures 
for OS were 71.4% and 40.0% (p = 0.126), respectively. The 
5-year RFS, DSS and OS in the whole cohort were 83.8%, 
79.3% and 66.3%, respectively. The 5-year DSS and OS for 
p16-positive and p16-negative cN0 OPSCC were 95.0% 
and 65.6% (p = 0.021) and 95.0% and 39.1% (p = 0.001), 
respectively.
Discussion
We reviewed 52 consecutive OPSCC patients with cN0 
disease over a 10-year period at our tertiary care hospital. 
In this series, surgery and (C)RT were both represented as 
elective treatment approaches for the neck. In only 13% 
of patients with curative treatment intent for early-stage 
disease, the neck was left untreated and was watchfully 
observed. The oropharynx has a rich lymphatic drainage, 
and OPSCC has a high propensity for metastatic spreading 
to regional lymph nodes. We have previously reported that 
at our institution during the same period 82% of all OPSCC 
patients had a cN+ neck [9], and in the present series, among 
those 18% without clinical lymph node metastasis, one-
fourth (22.6%) had occult metastases. In addition, in this 
series, three patients, all with a soft palate tumor, suffered a 
regional recurrence. Thus, our results support the paradigm 
that in OPSCC, patients only rarely present with cN0 neck 
and most of them in this subgroup still seem to need treat-
ment to the neck due to the high-risk occult metastases [14].
In terms of disease control, elective (C)RT and ND are 
generally regarded as equal treatment methods [14]. How-
ever, for most surgically treated patients (79%), adjuvant 
treatment was offered because of the size of the primary 
tumor, occult histologically verified neck metastases, or 
other adverse histopathological findings.
A single treatment modality with either definitive RT or 
surgery for early-stage OPSCC is generally recommended 
[6, 15, 16]. Roden et al. [17] reviewed 3247 early-stage ton-
sil cancer patients, and reported that surgery followed by RT 
resulted in a significantly improved OS (81%) as compared 
with surgery (67%) or RT (63%) alone. One can assume 
that the multimodality treatment group included patients 
with metastatic lymph nodes or other adverse pathologi-
cal features, and, therefore, the differences in survival seem 
considerable. The worst survival (52%) was among the 
group of surgically treated patients who did not have any 
elective treatment of the neck. Elective neck dissection pro-
vides important information regarding metastatic spread to 
regional lymph nodes necessitating postoperative RT or even 
CRT and thus the highest risk patients receive multimodality 
treatment [18]. This may explain the better outcome among 
surgically treated patients in their series [17]. Even though 
a single treatment modality is favored in early-stage disease, 
surgery alone seems to remain relatively rarely an option in 
OPSCC [17], as observed also in our series.
Treatment of OPSCC has been changing towards to a 
more oncological approach over the last few decades, as the 
rate of surgeries has been decreasing and patients receive 
more often CRT [19, 20]. However, according to some stud-
ies, patients with HPV-negative OPSCC are suggested to 
benefit from surgery [21, 22]. Our previous study revealed 
that surgery and oncological treatment were equally rep-
resented in Finland during 2000–2009. p16 status was not 
available at the time of treatment decision, and the chosen 
treatment did not differ according to p16 status. However, 
patients with anterior-wall OPSCC received more often 
oncological treatment than surgery [23].
Soft palate tumors are presumably more often diagnosed 
with cN0 neck compared with other oropharyngeal sublo-
calizations, such as tonsil or base of tongue [24]. During 
years 2000–2009 in Finland, 64% of the soft palate were 
Table 4  The three patients with regional recurrent disease
RT radiotherapy, ND neck dissection, SLNB sentinel lymph node 
biopsy, Gy gray, mo month, DWD died with disease, DNED died with 
no evidence of disease
Patient number 1 2 3
Age 69 55 49
Sex Female Male Male
Site Soft palate Soft palate Soft palate
Side Bilateral Bilateral Bilateral
T class T2 T2 T2
N class N0 (pN1) N0 N0
p16 Negative Negative Negative
HPV Positive Negative Negative
Treatment Surgery + RT Surgery + RT Surgery
Reconstruction No No No
ND No (bilateral 
SNLB)
No No
Neck RT Bilateral (56 Gy) Bilateral (60 Gy) No
RRFS time (mo) 7 16 3
Recurrence side Contralateral Ipsilateral Bilateral
Treatment Palliative RT ND + RT ND + RT
Status (mo) DWD (11.0) DWD (12.9) DNED (5.7)
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OPSCCs which were diagnosed without nodal involvement, 
as in the lateral and anterior wall corresponding 19% and 
22% (Jouhi L, unpublished data based on study data series, 
Oct. 24, 2018). High probability for soft palate tumors to be 
diagnosed without regional lymph node metastasis is prob-
ably related to HPV status. It is well established that soft 
palate OPSCCs are typically HPV negative [25], and that 
HPV-negative tumors less frequently present with regional 
lymph node metastasis [5]. Hence, in our material, regional 
recurrences did not occur in patients carrying a p16-positive 
tumor. However, in our series one of the patients, who devel-
oped a regional recurrence, had a p16-negative but HPV-
positive tumor. It has been previously reported that patients 
with this kind of discordant pattern of HPV and p16 may 
have a poor prognosis inspite of HPV positivity [26].
SLNB has been shown to detect occult neck disease reli-
ably in oral cancer and it can be used instead of elective 
neck dissection to stage the neck [27, 28]. Many studies on 
sentinel lymph node biopsy include patients with OPSCC 
as the examination can be technically performed in some 
OPSCCs [29]. The number of OPSCC patients in these stud-
ies, however, is usually low and the role of SLNB is less 
clear in OPSCC [29]. Presumably, SLNB is not often used 
in OPSCC. In our series, SLNB was performed only in one 
patient with a tumor in the soft palate, and it revealed an 
occult neck disease. The patient was thereafter given bilat-
eral neck RT but despite the treatment, a regional recurrence 
developed contralaterally. Thus, even a complementary ND 
would not have saved this patient from recurrent disease.
It seems that surgery may gain popularity in early-stage 
OPSCC management [2]. Trans-oral robotic surgery may 
be a feasible minimally invasive strategy for primary tumor 
resection with good functional outcome [7, 30]. In addition, 
histopathological data derived from the primary tumor and 
ND specimens may enable treatment intensification for the 
high-risk patients, while patients without adverse features 
may be treated safely with surgery only [15]. With this strat-
egy, the long-term side effects of (C)RT could be avoided. In 
addition, as second primary tumors are relatively common 
in OPSCC patients, an option remains to later deliver treat-
ment with RT.
OPSCC without regional lymph node metastasis is a 
minor but challenging patient group. Although our inves-
tigation covered a 10-year consecutive OPSCC population 
from an area with 1.6M inhabitants, the patient series with 
N0 neck remained fairly limited. Small number of patients 
and low incidence of RR hindered further statistical analysis, 
and consequently robust conclusions from the results can-
not be drawn. In spite of that, our material is a representa-
tive unselected cohort, as treatment of all head and neck 
cancers, including also early-stage disease, is centralized 
to our hospital within our catchment area. However, dur-
ing the long inclusion period of this study, the treatment 
paradigm was changing towards a more definitive (C)RT-
oriented approach, which resulted in some heterogeneity in 
the treatment.
We conclude that in our series regional recurrences were 
infrequent in patients treated for OPSCC with cN0 neck 
and occurred only in patients with soft palate tumors. In 
addition, the midline localization of the tumor may have 
had an impact on the outcome of these cases in our series. 
Therefore, this additional aspect may warrant careful con-
sideration in the treatment planning. Our results suggest that 
while the current overall prognosis of OPSCC nowadays is 
favorable and regional recurrences are infrequent, soft palate 
tumors may form a more aggressive subgroup being usually 
p16 negative and requiring often more intensive treatment.
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